MitoRx Therapeutics is a pre-clinical stage rare disease biotech company which has developed next generation mitochondrial sulfide donor small molecule drugs. Our MoA is the activation of an endogenous mitochondrial protection pathway (first-in-target, first-in-class) which protects mitochondrial function and integrity, muscle function and mass as well as healthspan. Positive results from our new class in models of Duchenne muscular dystrophy and primary mitochondrial disease will be published in early 2021.